New Real-World Evidence Presented by Organon at the American… – Quantisnow

New Real-World Evidence Presented by Organon at the American…  Quantisnow

Analysis of over 16,000 patients switched to HADLIMA® from HUMIRA® (adalimumab) showed a 1.3% switchback rate over a 12-month follow-up period1 Data… Real-world VA study: 16,322 patients switched Humira to Hadlima, 1.3% switchback, $132M estimated savings, $8,100 per-patient cost cut. Plus members following OGN get this by push and email at 10:00:00 ET – it reached us under a second after publication. Organon presented real-world data at the American College of Rheumatology meeting on a large switch of veterans from HUMIRA to its biosimilar HADLIMA. The study found a 1.3% switchback rate over 12 months and an estimated $132 million in savings for the VA system. For shareholders, the release is a promotional data point supporting HADLIMA's uptake in a major public payer, though it is a poster presentation based on one health system's records.

Written by Quantisnow AI from this release. Not financial advice. Organon presented a poster evaluating the switch of US Veterans Affairs patients from HUMIRA to HADLIMA, covering treatment, management and economic impacts. The study identified 16,322 veterans who transitioned from the originator HUMIRA to HADLIMA. Yes, the release says HADLIMA was exclusively selected by the VA to replace HUMIRA on its national formulary in 2024. Across the 28 sessions after earlier OGN headlines, the stock closed higher 14 times and lower 10 times, with a